Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 7:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 631 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Pancreatic Ductal Adenocarcinoma, Stage III Breast Cancer AJCC v7, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage III Lung Small Cell Carcinoma AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Small Cell Carcinoma AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Small Cell Carcinoma AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Small Cell Carcinoma AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma, Unresectable Lung Small Cell Carcinoma, Unresectable Pancreatic Adenocarcinoma, Unresectable Pancreatic Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
18F-Fluoromisonidazole, Cediranib Maleate, Laboratory Biomarker Analysis, Olaparib, Positron Emission Tomography
Other · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
14
States / cities
La Jolla, California • Sacramento, California • San Diego, California + 9 more
Conditions
Lung Cancer
Interventions
hypofractionated radiation therapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
2
States / cities
Stanford, California • Dallas, Texas
Conditions
Lung Cancer
Interventions
carboplatin, Gemcitabine, paclitaxel, vinorelbine, radiation therapy, Navelbine, Taxol
Drug · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Lung Cancer, Non-small-cell Lung Carcinoma
Interventions
Tarceva (erlotinib HCl)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
92
States / cities
Huntsville, Alabama • Anchorage, Alaska • Glendale, Arizona + 83 more
Conditions
Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion, Stage IV Non-small Cell Lung Cancer
Interventions
Tamibarotene, Placebo
Drug
Lead sponsor
CytRx
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Rancho Mirage, California • Kansas City, Kansas • Hackensack, New Jersey
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Atezolizumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years to 99 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
13
States / cities
Phoenix, Arizona • La Jolla, California • Chicago, Illinois + 10 more
Conditions
Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
Ponatinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Non-Small Cell Lung Cancer, Carcinoma
Interventions
Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T
Biological
Lead sponsor
Adaptimmune
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
14
States / cities
Duarte, California • Palo Alto, California • Miami, Florida + 11 more
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, protein expression analysis, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Greg Otterson
Other
Eligibility
18 Years to 120 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Solid Tumor, Non-small-cell Lung Cancer, Lung Cancer
Interventions
CO-1.01 and Cisplatin
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Sarasota, Florida • Nashville, Tennessee
Conditions
Lung Cancer
Interventions
Celecoxib, Docetaxel
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Lung Cancer, Pulmonary Complications, Radiation Fibrosis
Interventions
captopril
Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
87
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Renal Pelvis Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Malignant Solid Neoplasm, Metastatic Bladder Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Carcinoma, Metastatic Urethral Urothelial Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Lung Cancer AJCC v6, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Melanoma
Interventions
Ipilimumab, Nivolumab, Tocilizumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions
18F-Fluoromisonidazole, Carboplatin, Computed Tomography, External Beam Radiation Therapy, Fludeoxyglucose F-18, Image-Guided Adaptive Radiation Therapy, Laboratory Biomarker Analysis, Paclitaxel, Positron Emission Tomography
Drug · Procedure · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
29
States / cities
Palo Alto, California • Augusta, Georgia • Chicago, Illinois + 23 more
Conditions
Lung Cancer, Metastatic Cancer
Interventions
doxorubicin hydrochloride
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
2
States / cities
New York, New York • Columbus, Ohio
Conditions
Lung Cancer
Interventions
bevacizumab, carboplatin, pemetrexed
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Evanston, Illinois • Harvey, Illinois + 1 more
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
bortezomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Phase 1Phase 2 Interventional Results available

Abraxane and Alimta in Advanced Solid Tumors

NCT00470548
Conditions
Breast Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Abraxane, Alimta
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Sacramento, California
Conditions
Lung Cancer
Interventions
erlotinib hydrochloride
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Nashville, Tennessee + 1 more
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Pemetrexed Disodium, Sunitinib Malate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
129
States / cities
Anaheim, California • Arroyo Grande, California • Baldwin Park, California + 90 more
Conditions
Lung Cancer
Interventions
IPI-504
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
11
States / cities
Los Angeles, California • New Haven, Connecticut • Miami, Florida + 6 more
Conditions
Lung Cancer
Interventions
cetuximab, carboplatin, pemetrexed disodium, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
71
States / cities
Arroyo Grande, California • Castro Valley, California • Hayward, California + 56 more
Conditions
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Physical Performance Testing, Questionnaire Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Lung Cancer
Interventions
chemotherapy, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Nashville, Tennessee